DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Thursday, 3 September 2015



Robert Kargbo, Ph.D.Robert B. Kargbo, Ph.D., Senior Research Scientist I at Albany Molecular Research Inc. (AMRI), was born in Freetown, Sierra Leone. He completed his BSc (Hons) in Chemistry Fourah Bay College, University of Sierra Leone. He lectured at the College of Medicine and Allied Health Sciences in Freetown, Sierra Leone. He obtained a Ph.D. in Organic Chemistry from North Dakota State University (with Professor Gregory R. Cook). He received a number of awards including the Pfizer Global Reseach & Development Research Fellowship, McNair Scholar Award and Graduate Research Fellowship, ND-EPSCoR. Dr. Kargbo joined AMRI as a Senior Research Scientist, working his way to his current position of Senior Research Scientist I in the Medicinal Chemistry Department.
Dr. Kargbo spent most of his time at AMRI in projects involved in drug discovery for small biotech and large pharmaceutical clients. The most recent collaborative work involves the NIH National Institute of Neurological Disorders and Stroke as part of the Medicinal Chemistry for Neurotherapeutics Program (NINDS MCNP). Dr. Kargbo occasional review articles and maintains active Independent Research Projects.





Blogger (AMRI)

AMRI (Albany Molecular Research Inc.)
 – Present (1 year 3 months)Albany, New York Area
Highlight interesting event or discovery:
Blog posting: http://www.amrismartsourcing.com/amri-events/a-recap-of-the-florida-heterocyclic-and-synthetic-conference/

Senior Research Scientist I

AMRI (Albany Molecular Research Inc.)
 – Present (5 years 6 months)Albany, New York

Tetrahedron Letters Award 2014
Tetrahedron Letters Award 2014
View On SlideShare

Senior Research Scientist

 –  (1 year 11 months)Albany, New York


 –  (2 years 11 months)
• Expert in statistical and analytical experience in the manufacturing of high quality glass product for various customers.
• Organizes and directs resources effectively, efficiently and execute complex experimental plans.
• Collaborates to enhance team efforts through personal contributions.
• First recipient of the “Employer of the year award” in 2001.


 –  (1 year 9 months)FREETOWN SIERRA LEONE


North Dakota State University


Faculty Search Committee, Student Representative, North Dakota State University. Fargo, ND.
Laboratory Safety Program, Student Representative, North Dakota State University, Fargo, ND.
Organizer, New Graduate Welcome Ceremony. North Dakota State University, Fargo, ND.

Fourah Bay College

BS Chemistry (Hons)


Tricyclic Compounds and PBK Inhibitors Containing the Same(Link)

US 8,962,648
February 24, 2015
Synthesis of tricyclic compounds and their use as PBK inhibitors. These compounds are useful for the treatment of PBK related diseases, including cancer.

Synthesis of 3-benzazepines and azepino[4,5-b]heterocyclic ring systems via intramolecular Friedel–Crafts cyclization(Link)

Tetrahedron Letters
The intramolecular Friedel–Crafts cyclization was found to be effective for the synthesis of 3-benzazepines and azepino[4,5-b]heterocyclic ring systems using simple allylic bromides tethered to activated aromatic nuclei. Amongst the various Lewis acids screened, Bi(OTf)3 was found to be the most effective ‘ecofriendly’ catalyst for the cyclization.

An efficient one-pot synthesis of 2-substituted benzimidazoles via triacyloxyborane intermediates is reported. The mild protocol is efficient and tolerant of acid-labile functional groups.
  • shemi, Zohreh; Ahmed, Feryan; Gauuan, Jolicia F.

Preparation of thieno[2,3-c]quinoline derivatives as PKB inhibitors for treating cancer

PCT Int. Appl
Title compds. I [R1, R2, R3, and R4 independently = H, OH, halogen, CN, NO2, NH2, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkoxy, aryl, indanyl, heteroaryl, etc.; R5 = H or alkyl; X, Y and Z together form S-CR7=CR6, CH2-CH2-CH2, NR108-CH=CR109; wherein R6 = H, OH, alkyl or (un)substituted aryl; R7 = H, halo, or (un)substituted alkyl; R108 = H, or (un)substituted alkyl; R109 = H, CH3, or...more
  • di-Hashemi, Zohreh; Cui, Wenge; Gauuan, Polivina Jolicia F.; et al

Asymmetric Synthesis of Aminochromanes via Intramolecular Indium-Mediated Allylation of Chiral Hydrazones(Link)

J. Org. Chem.
August 24, 2009
Debasis Samanta, Robert B. Kargbo and Gregory R. Cook
J. Org. Chem., 2009, 74 (18), pp 7183–7186
Publication Date (Web): August 24, 2009 (Note)
DOI: 10.1021/jo901195g
The asymmetric intramolecular indium-mediated cyclization reaction delivers chromanes with excellent diastereoselectivity (68−91% yield, dr >99:1). The reaction was efficient for aryl substrates with both electron-withdrawing...more

Stereoselective Indium-Mediated Allylation Reactions(Link)

Current Organic Chemistry
Since the discovery that indium could affect a Barbier-type allylation of carbonyls in water over a decade ago, interest in the utility of indium metal and its salts to influence organic transformations has increased exponentially. Control of chemo-, regio-, and especially stereoselectivity in indium-mediated reactions has proven to be a challenge, however, examples of such discerning processes...more

Readily Accessible, Modular, and Tuneable BINOL 3,3‘-Perfluoroalkylsulfones: Highly Efficient Catalysts for Enantioselective In-Mediated Imine Allylation
March 13, 2007
Robert Kargbo, Yoko Takahashi, Santosh Bhor, Gregory R. Cook, Guy C. Lloyd-Jones, and Ian R. Shepperson
J. Am. Chem. Soc., 2007, 129 (13), pp 3846–3847
Publication Date (Web): March 13, 2007 (Communication)
DOI: 10.1021/ja070742t
Thia−Fries rearrangement of BINOL perfluoroalkylsulfonates affords readily derivatized novel mono- and disulfone ligands in just two steps from enantiomerically pure...more

Catalytic Enantioselective Indium-Mediated Allylation of Hydrazones

Gregory R. Cook, Robert Kargbo, and Bikash Maity
Org. Lett., 2005, 7 (13), pp 2767–2770
Publication Date (Web): May 28, 2005 (Letter)
DOI: 10.1021/ol051160o
A facile and highly selective indium-mediated allylation of hydrazones utilizing BINOL ligands is described. Chiral (R)-3,3‘-bistrifluoromethylBINOL afforded homoallylic amines in up to 97% ee with stoichiometric ligand. Employing only 10...more

Highly Diastereoselective Indium-Mediated Allylation of Chiral Hydrazones

Gregory R. Cook, Bikash C. Maity, and Robert Kargbo
Org. Lett., 2004, 6 (11), pp 1741–1743
Publication Date (Web): May 04, 2004 (Letter)
DOI: 10.1021/ol0496172
The indium-mediated allylation of chiral hydrazones was investigated. Essentially complete diastereoselectivity and quantitative yields were obtained for substrates derived from both aromatic and aliphatic aldehydes.

Synthetic applications of tris(pentafluorophenyl)borane

Hydrosilation of arom. compds. catalyzed by 1-4 mol% of tris(pentafluorophenyl)borane is a mild and selective addn. of Ph3SiH at room temp. Yields and conversion rates for this transformation are high and the reactivity order is esters >> ketone > aldehyde which is paradoxical to the normal reactivity pattern. Secondary benzylic alc. derivs. undergo allylation with allylsilanes in the...more

Asymmetric addition of organoindium reagent to hydrazones(Link)

Diss. Abstr. Int., B 2008, 69(4), 2332.
Dissertation (2008), 209 pp

Christopher Conway has been appointed to lead AMRI ’s discovery business strategy as SrVP of Discovery and Development and Global Commercial Sales.

Christopher Conway

Christopher Conway, Senior Vice President,
Global Sales and Marketing

Christopher Conway has been appointed to lead the company’s discovery business strategy as Senior Vice President of Discovery and Development and Global Commercial Sales.
September 3, 2015

Dear industry colleague,
As we continue to support the research and development that leads to the commercialization of pharmaceutical products, it is critical that we align our focus on R&D with the commercial demands of the market. Today, AMRI has announced an organizational change in our Discovery and Development Services (DDS) business. These changes are expected to drive top and bottom line growth for the Discovery and Development Solutions (DDS) business through strong commercial leadership; strengthen the DDS strategy and aggressively pursue the most valuable growth opportunities, externally and internally; and ensure that our service offerings are well aligned with your needs and the needs of the market.
Effective immediately, Christopher Conway has been appointed to lead the company’s discovery business strategy as Senior Vice President of Discovery and Development and Global Commercial Sales. In this role, Chris will head up the global Discovery and Development Solutions (DDS) business leading these businesses in the United States, Europe and Asia. Sales and marketing will also continue to report to him. He succeeds Michael A. Luther, Ph.D., MBA, who will be leaving AMRI to pursue other opportunities. We thank Dr. Luther for his efforts in moving the DDS business along over the last year and wish him the best in his future endeavors.
Related to this announcement, we would like to take the opportunity to announce the hiring of Rory Curtis, Ph.D., who has joined AMRI as Vice President of Discovery Biology and Pharmacology. Rory will also serve as site head with responsibility for scientific operations at AMRI’s Buffalo, N.Y. location. Rory was most recently Senior Director of Human Diseases in Discovery at Cubist Pharmaceuticals, where he developed Cubist’s antibacterial drug discovery into new disease areas such as pain, inflammation and gastro-intestinal disease. Before this, he held positions of increasing responsibility at Elixir Pharmaceuticals, Millennium Pharmaceuticals and Regeneron Pharmaceuticals.
Rory Curtis

Rory Curtis

Vice President of Discovery Biology and Pharmacology, Site Head AMRI Buffalo
In addition to Chris’ current direct reports and Rory, he will have a scientific leadership team reporting into him, which includes Michael P. Trova, Ph.D., Senior Vice President of Chemistry; Raj Shenoy, Senior Director of Global Chemical Development; and Pete Michels, Ph.D., Senior Director of Metabolism and Biotransformations.
Michael P. Trova, Ph.D.
Pete C. Michels, Ph.D., Senior Director, Chemical Development, Fermentation and Biocatalysis, AMRI
We are very excited about the future of AMRI Drug Discovery and Development and are pleased to welcome Rory to the AMRI discovery team. Market demand for our DDS services continues to grow and these changes will help us increase our market share and strengthen AMRI’s global position in Discovery and Development.
As we approach the second half of 2015, we are looking forward to working with you on a great number of new opportunities in 2016 and beyond. We appreciate your loyalty and support, and continue to remain dedicated to enhancing your pharmaceutical services experience from early discovery through to the commercialization and delivery of drug product. If you have any questions, please feel free to read today’s related press release atwww.amriglobal.com, or contact us here.

William S. Marth
President and CEO
Albany Molecular Research Inc. (AMRI)
William S. Marth. President and Chief Executive Officer Albany Molecular Research, Inc.

Albany Molecular Research Locations
Albany Molecular Research Inc. (AMRI)
26 Corporate Circle
Albany, NY 12203
Albany Molecular Research Inc. provides global contract research and manufacturing services to the pharmaceutical and biotechnology industries. Our services include Drug Discovery, such as medicinal chemistry, discovery biology and in vitro ADME; Development, such as pre-formulation, formulation and validation; and Manufacturing, such as cGMP API manufacturing.


AMRI SingaporeAMRI’s Singapore Research Centre, Pte. Ltd. provides chemistry and biology services to support drug discovery and development programs. AMRI is one of the first drug discovery R&D companies to establish operations in Singapore. Fully integrated with AMRI’s locations in the United States, Asia, and Europe, the Singapore centre offers medicinal chemistry services such as hit-to-lead andlead optimization as well as focused library synthesis / custom synthesis. In the area of biology / in vitro pharmacology, the Singapore Research Centre provides target validation; assay development; HTS; rapid production of SAR quality data; and in vitro ADMET support, including CYP inhibition, metabolic stability (liver microsome assays), and aqueous solubility. As a signatory to the World Patent Treaty, Singapore provides an environment that protects intellectual property, enabling our scientists to conduct proprietary and cutting-edge research on behalf of our customers.
Areas of Expertise: Discovery Services
Contact Information:
61 Science Park Road
#05-01 The Galen
Singapore Science Park II
Singapore 117525

Phone: +65-6398-5500
Fax: +65-6398-5511


AMRI Hyderabad IndiaThe Hyderabad Research Centre, Pvt. Ltd. (AMRHRC) is located in Hyderabad, India, an emerging technology metropolis located in South Central India.
All fully integrated with AMRI’s U.S.-based resources, this Centre’s core area of expertise is in the areas ofmedicinal chemistrysupport, chemical development, custom synthesis of scaffolds and building blocks, process development, GMP analytical services,scale-up and preparation of reference standards.


GRANT CARR, PH.D. Follow Grant Carr at Linked In

Robert Kargbo, Ph.D.

ROBERT B. KARGBO, PH.D. linkedin